28342945|t|Cognitive impairment in first-episode drug-na誰ve patients with schizophrenia: Relationships with serum concentrations of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor
28342945|a|Evidence suggests that brain-derived neurotrophic factor (BDNF) and glial cell line -derived neurotrophic factor (GDNF) are important in the regulation of synaptic plasticity, which plays a key role in the cognitive processes in psychiatric disorders. Our work aimed at exploring the associations between serum BDNF and GDNF levels and cognitive functions in first-episode drug-na誰ve (FEDN) patients with schizophrenia. The BDNF and GDNF levels of 58 FEDN patients and 55 age - and sex -matched healthy controls were measured and test subjects were examined using several neurocognitive tests including the verbal fluency test (VFT), the trail making test (TMT), the digit span test (DST), and the Stroop test. Patients performed significantly worse than controls in nearly all neurocognitive performances except the forward subscale part of the DST. BDNF levels were inversely correlated to TMT-part B scores and positively correlated to VFT-action in the FEDN group. GDNF levels showed a positive correlation with VFT-action scores and a negative correlation with TMT-part B scores of these patients. Current data suggests that cognitive dysfunction widely exists in the early stages of schizophrenia. BDNF and GDNF may be jointly contributed to the pathological mechanisms involved in cognitive impairment in FEDN patients with schizophrenia.
28342945	0	20	Cognitive impairment	T048	C0338656
28342945	24	37	first-episode	T079	C0439615
28342945	38	57	drug-na誰ve patients	T101	C0030705
28342945	63	76	schizophrenia	T048	C0036341
28342945	78	91	Relationships	T080	C0439849
28342945	97	117	serum concentrations	T081	C0683149
28342945	121	154	brain-derived neurotrophic factor	T116,T123	C0107103
28342945	159	202	glial cell line-derived neurotrophic factor	T116,T123	C0207072
28342945	226	259	brain-derived neurotrophic factor	T116,T123	C0107103
28342945	261	265	BDNF	T116,T123	C0107103
28342945	271	315	glial cell line -derived neurotrophic factor	T116,T123	C0207072
28342945	317	321	GDNF	T116,T123	C0207072
28342945	344	377	regulation of synaptic plasticity	T042	C1326639
28342945	409	428	cognitive processes	T041	C0871689
28342945	432	453	psychiatric disorders	T048	C0004936
28342945	487	499	associations	T080	C0439849
28342945	508	513	serum	T031	C0229671
28342945	514	518	BDNF	T116,T123	C0107103
28342945	523	527	GDNF	T116,T123	C0207072
28342945	539	558	cognitive functions	T041	C0392335
28342945	562	602	first-episode drug-na誰ve (FEDN) patients	T101	C0030705
28342945	608	621	schizophrenia	T048	C0036341
28342945	627	631	BDNF	T116,T123	C0107103
28342945	636	640	GDNF	T116,T123	C0207072
28342945	654	667	FEDN patients	T101	C0030705
28342945	675	678	age	T032	C0001779
28342945	685	688	sex	T032	C1522384
28342945	698	714	healthy controls	T080	C2986479
28342945	733	746	test subjects	T096	C0681850
28342945	775	795	neurocognitive tests	T060	C0872227
28342945	810	829	verbal fluency test	T060	C0033905
28342945	831	834	VFT	T060	C0033905
28342945	841	858	trail making test	T170	C0040604
28342945	860	863	TMT	T170	C0040604
28342945	870	885	digit span test	T170	C0451577
28342945	887	890	DST	T170	C0451577
28342945	901	912	Stroop test	T060	C2718024
28342945	914	922	Patients	T101	C0030705
28342945	958	966	controls	T096	C0009932
28342945	981	1008	neurocognitive performances	T060	C0872227
28342945	1049	1052	DST	T170	C0451577
28342945	1054	1058	BDNF	T116,T123	C0107103
28342945	1059	1065	levels	T080	C0441889
28342945	1095	1112	TMT-part B scores	T080	C0237855
28342945	1142	1152	VFT-action	T060	C0033905
28342945	1172	1176	GDNF	T116,T123	C0207072
28342945	1177	1183	levels	T080	C0441889
28342945	1219	1236	VFT-action scores	T080	C0237855
28342945	1269	1286	TMT-part B scores	T080	C0237855
28342945	1296	1304	patients	T101	C0030705
28342945	1333	1354	cognitive dysfunction	T048	C0338656
28342945	1376	1388	early stages	T079	C2363430
28342945	1392	1405	schizophrenia	T048	C0036341
28342945	1407	1411	BDNF	T116,T123	C0107103
28342945	1416	1420	GDNF	T116,T123	C0207072
28342945	1455	1467	pathological	T169	C1521733
28342945	1468	1478	mechanisms	T169	C0441712
28342945	1491	1511	cognitive impairment	T048	C0338656
28342945	1515	1528	FEDN patients	T101	C0030705
28342945	1534	1547	schizophrenia	T048	C0036341